Solara Active Pharma Sciences Limited — Others, 15-05-2025: Statement of deviation(s) or variation(s) under Reg. 32

Solara Active Pharma Sciences Limited has confirmed no deviation in the use of funds raised through its ₹157.48 Cr Rights Issue. The company has fully utilized ₹118.61 Cr for repayment of borrowings and ₹35.87 Cr for general corporate purposes as planned. The Audit Committee reviewed and approved the fund usage, affirming disciplined financial management that aligns with the company’s operational objectives, providing assurance to shareholders about effective capital deployment.